Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Go back to Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 14.66 +0.04 (0.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.62 | 52 Week High | $5.58 | |||
| Open | $14.68 | 52 Week Low | $3.60 | |||
| Day High | $14.71 | P/E | N/A | |||
| Day Low | $14.63 | EPS | $0.00 | |||
| Volume | 380,956 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 42.03 -0.47 (1.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.50 | 52 Week High | $44.76 | |||
| Open | $42.34 | 52 Week Low | $36.81 | |||
| Day High | $42.38 | P/E | N/A | |||
| Day Low | $42.03 | EPS | $0.00 | |||
| Volume | 123,984 | |||||
